Semaglutide mimics the action of the natural protein glucagon-like peptide 1(GLP-1), a hormone ... Ozempic, or semaglutide, is a GLP-1 agonist, meaning its molecules mimic the structure of GLP-1, ...

Most people regain some of the weight they lost after stopping semaglutide. However, physical activity and a balanced diet may help you keep some weight off. Share on Pinterest LeoPatrizi/Getty ...

The findings of this study provide initial prospective evidence that low-dose semaglutide can reduce craving and some drinking outcomes, justifying larger clinical trials to evaluate glucagon-like ...

About The Study: This cohort study found that key sociodemographic, health care, and clinical factors are associated with receipt of semaglutide, a novel glucagon-like peptide-1 (GLP-1 ...

Research reveals semaglutide's effectiveness in decreasing alcohol consumption and cravings, highlighting its potential for treating alcohol use disorder.

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

Rani Therapeutics (RANI) announced new pharmacokinetic and pharmacodynamic data from a preclinical study evaluating the oral delivery of the ...

At least nine patients using the glucagon-like peptide 1 (GLP-1) receptor agonists semaglutide and tirzepatide developed ophthalmic complications, of whom seven had nonarteritic anterior ischemic ...